Light Sciences Oncology (LSO) plans to use the funds in the continued development of Light Infusion Therapy (Litx), which includes two ongoing Phase III clinical trials in patients with hepatocellular carcinoma and metastatic colorectal cancer, a planned Phase III trial in glioblastoma multiforme, and early stage clinical trials in benign prostatic hyperplasia.
Leerink Swann acted as exclusive placement agent and exclusive financial advisor in connection with the transaction.
Llew Keltner, president and CEO of LSO, said: “The series C funds combined with our substantial cash reserves will allow us to continue to move forward with all aspects of our development plan in a timely manner.”